{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:29:59Z","timestamp":1782019799375,"version":"3.54.5"},"reference-count":26,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7\u00a0+\u00a03 in adults with newly-diagnosed acute myeloid leukemia (AML), irrespective of the\u00a0FLT3-mutation status. Here, we evaluated adding sorafenib to cladribine, high-dose cytarabine, granulocyte colony\u2013stimulating factor, and mitoxantrone (CLAG-M) in a phase 1\/2 trial of 81 adults aged\u00a0\u226460 years with newly diagnosed AML. Forty-six patients were treated in phase 1 with escalating doses of sorafenib and mitoxantrone. No maximum tolerated dose was reached, and a regimen including mitoxantrone 18\u00a0mg\/m2\u00a0per day and sorafenib 400\u00a0mg twice daily was declared the recommended phase 2 dose (RP2D). Among 41 patients treated at RP2D, a measurable residual disease\u2013negative complete remission (MRD\u2013\u00a0CR) rate of 83% was obtained. Four-week mortality was 2%. One-year overall survival (OS) and EFS were 80% and 76%, without differences in MRD\u2013\u00a0CR rates, OS, or EFS between patients with or without\u00a0FLT3-mutated disease. Comparing outcomes using CLAG-M\/sorafenib with those of a matched cohort of 76 patients treated with CLAG-M alone, multivariable-adjusted survival estimates were improved for 41 patients receiving CLAG-M\/sorafenib at RP2D (OS:\u00a0hazard ratio,0.24 [95%\u00a0confidence interval, 0.07-0.82];\u00a0P\u00a0= .023; EFS: hazard ratio, 0.16 [95%\u00a0confidence interval, 0.05-0.53];\u00a0P\u00a0=\u00a0.003). Benefit was limited to patients with intermediate-risk disease (univariate analysis:\u00a0P\u00a0= .01 for OS; P\u00a0= .02 for EFS). These data suggest that CLAG-M\/sorafenib is safe and improves OS and EFS relative to CLAG-M alone, with\u00a0benefits primarily in patients with intermediate-risk disease. The trial was registered at\u00a0www.clinicaltrials.gov as #NCT02728050.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010392","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T21:03:11Z","timestamp":1687294991000},"page":"4950-4961","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Phase 1\/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-0748","authenticated-orcid":false,"given":"Anna B.","family":"Halpern","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"3Department of Hematology, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, University of Seville, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"4Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-2019","authenticated-orcid":false,"given":"Kelsey-Leigh A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth M.","family":"Percival","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-9463","authenticated-orcid":false,"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-7773","authenticated-orcid":false,"given":"Jacob S.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis L.","family":"Abkowitz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-4680","authenticated-orcid":false,"given":"Johnnie J.","family":"Orozco","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"5Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siob\u00e1n B.","family":"Keel","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-5972","authenticated-orcid":false,"given":"Paul C.","family":"Hendrie","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7839","authenticated-orcid":false,"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"5Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cristina","family":"Ghiuzeli","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"6Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"3","key":"2023091115342387200_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"2023091115342387200_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023091115342387200_bib3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"2023091115342387200_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023091115342387200_bib5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","article-title":"Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial","volume":"35","author":"R\u00f6llig","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2023091115342387200_bib6","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023091115342387200_bib7","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms","volume":"32","author":"Halpern","year":"2018","journal-title":"Leukemia"},{"issue":"33","key":"2023091115342387200_bib8","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023091115342387200_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2023091115342387200_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023091115342387200_bib11","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"9","key":"2023091115342387200_bib12","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023091115342387200_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: is it time to move toward a minimal residual disease-based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023091115342387200_bib14","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023091115342387200_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.2022.281631","article-title":"Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"108","author":"Rodr\u00edguez-Arbol\u00ed","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2023091115342387200_bib16","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","article-title":"Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"104","author":"Halpern","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2023091115342387200_bib17","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/cancers14122934","article-title":"Phase 1\/2 trial of CLAG-M with dose-escalated mitoxantrone in combination with fractionated-dose gemtuzumab ozogamicin for newly diagnosed acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"14","author":"Godwin","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"2023091115342387200_bib18","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"2023091115342387200_bib19","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2023091115342387200_bib20","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023091115342387200_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2023091115342387200_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3324\/haematol.2022.281585","article-title":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","volume":"108","author":"Orvain","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"2023091115342387200_bib23","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2023091115342387200_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.annonc.2022.11.004","article-title":"Moving toward individualized target-based therapies in acute myeloid leukemia","volume":"34","author":"Bazinet","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"2023091115342387200_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/leu.2014.54","article-title":"Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2014","journal-title":"Leukemia"},{"issue":"25","key":"2023091115342387200_bib26","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4950\/2076890\/blooda_adv-2023-010392-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4950\/2076890\/blooda_adv-2023-010392-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:35:20Z","timestamp":1694446520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4950\/496465\/Phase-1-2-study-of-sorafenib-added-to-cladribine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010392","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}